Skip to content

Opening book details…

Can I read Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: Follow-up analysis of a multicenter prospective phase 3 imaging trial on EtoBox?

Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: Follow-up analysis of a multicenter prospective phase 3 imaging trial by L. Djaïleb; W.R. Armstrong; D. Thompson; A. Gafita; A. Farolfi; T.R. Grogan; W.P. Fendler; J. Czernin; T.A. Hope; J. Calais is a Medicine article available to read on EtoBox.

What is Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: Follow-up analysis of a multicenter prospective phase 3 imaging trial about?

Purpose/background To assess the added prognostic value of pre-surgical PSMA PET for early biochemical recurrence (BCR) progression free-survival (BCR-PFS) compared to pre-surgical CAPRA (Cancer of the Prostate Risk Assessment) and post-surgical CAPRA-S scores in patients treated with radical prostatectomy (RP) and Pelvic Lymph Node Dissection (PLND) with intermediate-risk (IR) to high-risk (HR) prostate cancer (PCa). Methods This is a follow-up study of the surgery cohort included in the multicenter prospective phase 3 imaging trial (n =277; NCT03368547, NCT02611882, NCT02919111), which assessed the diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to RP and PLND in patients with IR and HR PCa. Each PSMA-PET scan was read by three blinded independent readers. PSMA PET prostate uptake (low vs. high), PSMA PET extra-prostatic disease (N/M), CAPRA and CAPRA-S score were used to assess risk of BCR. Patients were followed up after RP by the local investigators using electronic medical records. BCR was defined by a prostate-specific antigen (PSA) level ≥ 0.2ng/mL after RP or an initiation of PCa specific secondary treatment (> 6 months after surgery). U

Who reads Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: Follow-up analysis of a multicenter prospective phase 3 imaging trial?

It is typically read by researchers, students, and practitioners in Medicine.

Author
L. Djaïleb; W.R. Armstrong; D. Thompson; A. Gafita; A. Farolfi; T.R. Grogan; W.P. Fendler; J. Czernin; T.A. Hope; J. Calais
Publisher
Elsevier BV
Published
2023
Language
EN
Field
Medicine (Health Sciences)

More by L. Djaïleb; W.R. Armstrong; D. Thompson; A. Gafita; A. Farolfi; T.R. Grogan; W.P. Fendler; J. Czernin; T.A. Hope; J. Calais

Browse all works by L. Djaïleb; W.R. Armstrong; D. Thompson; A. Gafita; A. Farolfi; T.R. Grogan; W.P. Fendler; J. Czernin; T.A. Hope; J. Calais